The acute ischemic stroke (AIS) market comprises products that help diagnose and treat blocked or ruptured blood vessels in the brain. Devices like cerebral thrombectomy systems are utilized to remove blood clots causing a blockage, while thrombolytic drugs such as tissue plasminogen activators (tPA) help dissolve clots. Advancements in diagnostics allow faster detection of stroke subtypes to determine the most suitable treatment approaches.
The Global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 10612.22 Bn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the acute ischemic stroke (AIS) market are F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc. The rising geriatric population coupled with the increasing prevalence of cardiovascular diseases worldwide is fueling the demand for AIS treatments. According to statistics, over 13 million people suffer a stroke annually across the globe. Several pharmaceutical companies are focusing on emerging economies in Asia Pacific and Latin America to tap the growth opportunities.
The growing demand can be attributed to the rising geriatric population who are more prone to strokes. Additionally, increasing lifestyle diseases such as diabetes, hypertension and obesity are contributing to the risk of ischemic strokes at younger ages as well. The market is witnessing high demand for advanced treatments such as mechanical thrombectomy devices and newer generation thrombolytic drugs with improved efficacy and safety profiles.
Major players are collaborating with hospitals, diagnostic companies and startups to expand their geographic presence. Initiatives are being undertaken to spread awareness about early symptoms of stroke and the importance of rapid treatment. Telestroke technologies allowing remote diagnosis and treatment monitoring are being introduced across rural regions globally to make advanced care accessible to all.
Market key trends
The emergence of novel drugs that can safely dissolve clots without increasing bleeding risks is one of the key trends in the Acute Ischemic Stroke Market Demand. Biologics targeting specific clot-forming molecules are being evaluated for safer recanalization compared to traditional thrombolytic therapies. Another notable trend is the advent of minimally invasive thrombectomy devices. New generation stent retrievers and aspiration systems are helping achieve higher recanalization rates with reduced procedural risks like embolization to unaffected brain regions. This is improving clinical outcomes especially for patients arriving late to hospitals. Growing focus on preventive care and vascular risk monitoring is also playing a role in positively shaping the market outlook.
Porter’s Analysis
Threat of new entrants: Low barriers to entry for stroke treatment.
Bargaining power of buyers: Large buyer groups like hospitals have significant influence on prices of stroke drugs and devices.
Bargaining power of suppliers: Suppliers of raw materials and components have moderate bargaining power as they are essential for innovation.
Threat of new substitutes: New treatment approaches act as substitutes that can affect existing players.
Competitive rivalry: Strong competition among large players to develop novel therapies and acquire smaller companies.
Geographical regions
North America currently accounts for the largest share in the global AIS market owing to aggressive adoption of advanced stroke treatments. The U.S. market specifically contributes significantly due to rising awareness initiatives and availability of reimbursement.
Asia Pacific is poised to grow at the fastest pace during the forecast period driven by increasing healthcare expenditure, large patient base, and rising focus of key players on emerging countries to tap unmet needs. Expanding medical tourism across India & China further aids the regional market expansion.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it